Leonard Guarente

Guarente has a clear and durable longevity vision centered on extending healthy lifespan by targeting aging mechanisms, especially NAD/sirtuin/metabolic pathways, and translating them into interventions. The evidence supports ambition and scientific specificity, but it is less strong on a concrete public roadmap, timelines, or a broad field-defining vision for ending aging or full rejuvenation.

Citation metrics are the primary signal for this dimension, and the OpenAlex data show field-defining scientific influence: h-index 117, 71,187 citations, and multiple foundational Sir2/SIRT1/NAD/longevity papers with roughly 1,500-3,500 citations each. The most-cited works directly align with major longevity mechanisms, including sirtuins, NAD-dependent deacetylation, calorie restriction, yeast aging, C. elegans lifespan extension, and mammalian SIRT biology. This supports a very high scientific-impact score, though not a perfect 10 because the provided evidence does not include independent synthesis explicitly crediting him with founding or transforming the field beyond citation weight.

There is limited evidence of longevity-oriented institution-building through Elysium Health, but no disclosed personal investments, donations, fund allocations, or capital amounts. The available evidence supports involvement as a founder/scientific leader rather than demonstrated deployment of his own or controlled capital.

Guarente shows above-average strategic taste through a coherent, mechanism-led longevity thesis: sirtuins, NAD metabolism, metabolic regulation, and calorie-restriction biology as routes to aging intervention. The evidence supports an early and concentrated research-to-translation strategy, especially via Elysium Health, but does not establish detailed counterfactual importance, timing of bets, or broad capital-allocation judgment. This is strong for thesis coherence and field-relevant translation, weaker for documented contrarianism or measurable deployment impact.

The dimension applies, but the supplied evidence provides only weak, mostly self-published indications of field-building. Elysium-related sources suggest Guarente had a leadership/co-founder/founder role in a longevity company, which could count as creating an organization that made longevity products or research more public-facing, but the structured facts say no founded organizations were found and there is no independent or primary corroboration in the evidence set. His MIT lab's role in sirtuins is relevant to scientific impact, but it is not enough here to show creation of organizations, programs, communities, protocols, or funding paths.

Guarente has moderate evidence of bravery/conviction: he publicly defended sirtuins and NAD-related longevity work amid controversy and uncertainty, and published at least one result that challenged an existing view about rapamycin mimicking calorie restriction. However, the evidence mostly shows scientific disagreement and public defense within normal academic/commercial discourse, not major career sacrifice, exceptional personal risk, or self-experimentation.

Guarente shows strong second-order scientific leverage through very high citation impact and heavily cited sirtuin/NAD/longevity papers that appear to have helped create substantial follow-on research activity. The evidence supports field-building within academic aging biology more clearly than capital, policy, founder, or public-movement leverage.